LUMOS PHARMA, INC. — Revenue by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/567f8fd2-737b-46d5-931a-5323cb06e0dd/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2023 | $2.1M | 2023-01-01 – 2023-12-31 | evidence 0001126234-24-000025 |
| FY 2022 | $1.5M | 2022-01-01 – 2022-12-31 | evidence 0001126234-24-000025 |
| FY 2021 | $230.0k | 2021-01-01 – 2021-12-31 | evidence 0001126234-22-000021 |
| FY 2020 | $168.0k | 2020-01-01 – 2020-12-31 | evidence 0001126234-21-000034 |
| FY 2019 | $0 | 2019-01-01 – 2019-12-31 | evidence 0001126234-21-000034 |
| FY 2018 | $12.5M | 2018-01-01 – 2018-12-31 | evidence 0001126234-19-000026 |
| FY 2017 | $28.7M | 2017-01-01 – 2017-12-31 | evidence 0001126234-19-000026 |
| FY 2016 | $3.5M | 2016-01-01 – 2016-12-31 | evidence 0001126234-19-000026 |
| FY 2015 | $68.5M | 2015-01-01 – 2015-12-31 | evidence 0001126234-18-000026 |
| FY 2014 | $172.6M | 2014-01-01 – 2014-12-31 | evidence 0001126234-15-000054 |
| FY 2013 | $1.1M | 2013-01-01 – 2013-12-31 | evidence 0001126234-15-000054 |
| FY 2012 | $1.7M | 2012-01-01 – 2012-12-31 | evidence 0001126234-15-000054 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
LUMOS PHARMA, INC. — all facts · Net Income · Operating Income